Yanggang Hong

Mr. Yanggang Hong

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YHYanggang Hong
Yanggang Hong
JLJiajun Li
Jiajun Li
YQYunxi Qiu
Yunxi Qiu
YWYi Wang
Yi Wang
ZDZhuoyi Du
Zhuoyi Du
SXSongjian Xin
Songjian Xin
Background: Per- and polyfluorinated alkyl substances (PFAS) are persistent environmental pollutants with known bioaccumulation potential and growing evidence of an association with cancer risk. However, the molecular mechanisms potentially linking PFAS exposure to carcinogenesis remain poorly understood. This study integrates computational toxicology and bioinformatics approaches to explore how PFAS-related molecular targets and pathways may overlap with those altered in six cancer types: breast carcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, prostate adenocarcinoma, thyroid cancer, and uterine corpus endometrial carcinoma, all of which have been previously implicated in PFAS-related research. Methods: Potential protein targets of perfluorooctanoic acid and perfluorooctane sulfonic acid were predicted using the Comparative Toxicogenomics Database and SwissTargetPrediction. Differentially expressed genes were identified from The Cancer Genome Atlas using the edgeR package. Protein–protein interaction networks were constructed via STRING, and enrichment analysis was performed using Metascape. Molecular docking was conducted using AutoDock to estimate PFAS-protein binding energies. Results: PFAS-related targets were associated with dysregulation of key cancer-related pathways, including cell cycle regulation, inflammatory responses, metabolic reprogramming, and DNA repair. Core targets such as CDC20, CCND1, MYC, BIRC5, PTEN, and IL6 were identified across multiple cancers. Molecular docking predicted strong binding energies between PFAS and several of these targets, supporting their potential relevance in cancer-associated molecular processes. Conclusion: This study provides a hypothesis-generating toxicogenomic framework for exploring PFAS-associated molecular alterations across cancer types. These findings highlight potential PFAS-related targets and pathways that warrant further experimental investigation to better understand their relevance to human health and cancer risk.

17 November 2024 in Reproductive Toxicology
Verified
Journal Article
Closed access
YHYanggang Hong
Yanggang Hong
YWYi Wang
Yi Wang
DWDeqi Wang
Deqi Wang
QYQichao Yuan
Qichao Yuan
ZYZihan Yang
Zihan Yang
CDChuncao Deng
Chuncao Deng

2 November 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YHYanggang Hong
Yanggang Hong
YWYi Wang
Yi Wang
WSWanyi Shu
Wanyi Shu

27 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YHYanggang Hong
Yanggang Hong
JLJiajun Li
Jiajun Li
NXNuo Xu
Nuo Xu
WSWanyi Shu
Wanyi Shu
FCFeng Chen
Feng Chen
QLQian Li
Qian Li
Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Despite therapeutic advances, there is a critical need to identify novel, effective, and safe drug targets to improve precision treatment strategies.Methods: We developed a multi-layered framework integrating Mendelian randomization (MR), colocalization analysis, genome-wide association study (GWAS) data, and expression quantitative trait loci (eQTLs) to prioritize causal and druggable genes in CRC. Single-cell and bulk RNA sequencing were used to characterize gene expression within the tumor microenvironment. Phenome-wide association studies (PheWAS) assessed off-target effects, and drug repurposing potential was evaluated using OpenTargets, DrugBank, and DGIdb. Validation of key targets was performed through RT-qPCR and immunohistochemistry (IHC) in CRC patient samples.Results: Out of 4,479 druggable genes, MR analysis identified 47 candidates significantly associated with CRC risk. Six genes (TFRC, TNFSF14, LAMC1, PLK1, TYMS, and TSSK6) demonstrated strong colocalization signals and were further validated across replication datasets and subtype-stratified analyses. PheWAS analysis revealed minimal off-target effects for these genes. Notably, several of these genes have already been targeted by existing or investigational drugs, suggesting potential for repurposing. These genes exhibited distinct expression patterns in tumor and stromal cell types and were differentially expressed in CRC versus normal tissues. Among them, TNFSF14, an immune modulator, is particularly involved in regulating T cell activation within the tumor microenvironment.Conclusion: This study identifies and validates six promising druggable targets for CRC, providing a strong foundation for future preclinical studies. These findings open avenues for advancing precision oncology and drug repurposing strategies in CRC treatment, contributing to the development of more effective and personalized therapeutic approaches.

16 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YHYanggang Hong
Yanggang Hong
JLJiajun Li
Jiajun Li
ZDZhuoyi Du
Zhuoyi Du
NXNuo Xu
Nuo Xu
QYQianru Yang
Qianru Yang
WSWanyi Shu
Wanyi Shu
Background: Estrogen receptor-positive (ER+) breast cancer is the most common molecular subtype of breast cancer and is strongly influenced by hormonal and environmental factors. Endocrine-disrupting chemicals (EDCs), which interfere with hormone signaling, have been suggested to contribute to ER+ breast cancer risk, but causal mechanisms remain unclear. Methods: We integrated chemical-gene interaction data from the TEDX and CTD databases with large-scale genomic datasets to investigate the relationship between EDC-regulated gene expression and ER+ breast cancer. A total of 5797 EDC-related genes were identified and filtered using cis-expression quantitative trait loci (cis-eQTL) data from eQTLGen. Mendelian randomization (MR) and colocalization analyses were performed using ER+ breast cancer GWAS summary statistics to assess causal associations and shared genetic signals. Interacting EDCs were mapped to colocalized genes. Results: Among 4207 genes with available cis-eQTLs, 50 showed statistically significant associations (FDR < 0.05) with ER+ breast cancer. Of these, 24 genes, including CIRBP, JMJD1C, and TET2, demonstrated strong evidence of colocalization. Key EDCs, such as bisphenol A and phthalates, were identified to interact with multiple high-risk genes, suggesting potential environmental drivers of ER+ breast cancer. Conclusion: This study provides genetic evidence supporting the causal role of EDC-regulated gene expression in ER+ breast cancer. The integration of MR, colocalization, and chemical-gene networks offers a novel framework for identifying environmentally relevant risk factors and contributes to understanding the gene-environment mechanisms underlying hormone-dependent cancers.

27 May 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
JLJiajun Li
Jiajun Li
NXNuo Xu
Nuo Xu
LHLeyin Hu
Leyin Hu
JXJiayue Xu
Jiayue Xu
YHYifan Huang
Yifan Huang
HYHuajun Ye
Huajun Ye
Background Chaperonin containing TCP1 subunit 5 (CCT5), a vital component of the molecular chaperonin complex, has been implicated in tumorigenesis, cancer stemness maintenance, and therapeutic resistance. Nevertheless, its comprehensive roles in pan-cancer progression, underlying biological functions, and potential as a predictor of immunotherapy response remains poorly understood. Methods We performed a comprehensive multi-omics pan-cancer analysis of CCT5 across 33 cancer types, integrating bulk RNA-seq, single-cell RNA-seq (scRNA-seq), and spatial transcriptomics data. CCT5 expression patterns, prognostic relevance, stemness association, and immune microenvironment relationships were evaluated. A novel CCT5-based signature (CCT5.Sig) was developed using machine learning on 23 immune checkpoint blockade (ICB) cohorts (n = 1394) spanning eight cancer types. Model performance was assessed using AUC metrics and survival analyses. Results CCT5 was significantly overexpressed in tumor tissues and primarily localized to malignant and cycling cells. High CCT5 expression correlated with poor prognosis in multiple cancers and was enriched in oncogenic, cell cycle, and DNA damage repair pathways. CCT5 expression was positively associated with mRNAsi, mDNAsi, and CytoTRACE scores, indicating a role in stemness maintenance. Furthermore, CCT5-high tumors exhibited immune-cold phenotypes, with reduced TILs and CD8⁺ T cell activity. The CCT5.Sig model, based on genes co-expressed with CCT5, achieved superior predictive accuracy for ICB response (AUC = 0.82 in validation and 0.76 in independent testing), outperforming existing pan-cancer signatures. Conclusion This study reveals the multifaceted oncogenic roles of CCT5 and highlights its potential as a pan-cancer biomarker for prognosis and immunotherapy response. The machine learning-derived CCT5.Sig model provides a robust tool for patient stratification and may inform personalized immunotherapy strategies. Graphical abstract